1
|
Kayıkcioglu M, Başaran Ö, Doğan V, Mert KU, Mert GÖ, Özdemir İH, Rencüzoğulları İ, Karadeniz FÖ, Tekinalp M, Aşkın L, Demirelli S, Gencer E, Bekar L, Aktaş M, Resulzade MM, Kalçık M, Aksan G, Cinier G, Akay KH, Pekel N, Utku Şenol, Demir V, İnci S, Derviş E, Özlek B, Özlek E, Çelik O, Çil C, Biteker M. Misperceptions and management of LDL-cholesterol in secondary prevention of patients with familial hypercholesterolemia in cardiology practice: Real-life evidence from the EPHESUS registry. J Clin Lipidol 2023; 17:732-742. [PMID: 38072583 DOI: 10.1016/j.jacl.2023.09.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2023] [Revised: 09/11/2023] [Accepted: 09/15/2023] [Indexed: 12/18/2023]
Abstract
BACKGROUND AND AIMS Familial hypercholesterolemia (FH) is a common inherited disease, leading to premature atherosclerotic cardiovascular disease (ASCVD) due to elevated low-density lipoprotein cholesterol (LDL-C) levels. Achieving LDL-C goals is extremely important for preventing the complications of this fatal disease. We evaluated the management of FH patients with ASCVD in cardiology practice. METHODS We analyzed patients with ASCVD from the nationwide EPHESUS registry, which was conducted in 40 cardiology outpatient clinics, and compared those with and without FH. RESULTS Of the 1482 consecutively enrolled patients with ASCVD, 618 (41.7%) had FH, among which 455 were categorized as 'Possible FH' and 163 as 'Probable or Definite FH'. Proposed LDL-C goals were not attained in more than 90% of the patients with FH. The proportion of those on statin therapy was 77% for possible and 91% for probable or definite FH, whereas 34.2 % and 59.4% were in use of high-intensity statins, respectively. None of the patients were on PCSK-9 inhibitors, and only 2 used ezetimibe. Adverse media coverage was the most common cause of statin discontinuation (32.5% in 'possible FH' and 45.7% in 'probable/definite FH'). The negative impact of media in the decision to stop lipid lowering therapy (LLT) was increasing with education level. CONCLUSIONS In real life most of the FH patients with ASCVD are undertreated in cardiology practice regarding statin dosing and combined LLT. Drug discontinuation rates are notably high and are mostly media-related, and side effects very rarely cause cessation of LLT. Urgent measures are needed to increase the awareness of FH among healthcare providers and patients and to develop improved treatment strategies aimed at preventing the complications of FH.
Collapse
Affiliation(s)
- Meral Kayıkcioglu
- Department of Cardiology (Dr Kayıkcioglu), Ege University Faculty of Medicine, İzmir, Turkey.
| | - Özcan Başaran
- Department of Cardiology (Drs Başaran, Doğan, Özlek, Özlek, Çelik), Muğla Sıtkı Koçman University Faculty of Medicine, Muğla, Turkey
| | - Volkan Doğan
- Department of Cardiology (Drs Başaran, Doğan, Özlek, Özlek, Çelik), Muğla Sıtkı Koçman University Faculty of Medicine, Muğla, Turkey
| | - Kadir Uğur Mert
- Department of Cardiology (Dr Mert), Eskişehir Osmangazi University Faculty of Medicine, Eskişehir, Turkey
| | - Gurbet Özge Mert
- Department of Cardiology (Dr Mert), Eskişehir Osmangazi University Faculty of Medicine, Eskişehir, Turkey
| | | | - İbrahim Rencüzoğulları
- Department of Cardiology (Dr Rencüzoğulları), Kafkas University Faculty of Medicine, Kars, Turkey
| | - Fatma Özpamuk Karadeniz
- Department of Cardiology (Dr Karadeniz), Karamanoglu Mehmetbey University Faculty of Medicine, Karaman, Turkey
| | - Mehmet Tekinalp
- Department of Cardiology (Dr Tekinalp), Necip Fazıl State Hospital, Kahramanmaras, Turkey
| | - Lütfü Aşkın
- Department of Cardiology (Dr Aşkın), Dr. Ersin Arslan Education and Research Hospital, Gaziantep, Turkey
| | - Selami Demirelli
- Department of Cardiology (Dr Demirelli), Kayseri City Hospital, Kayseri, Turkey
| | - Erkan Gencer
- Department of Cardiology (Dr Gencer), Şanlıurfa Mehmet Akif İnan Education and Research Hospital, Şanlıurfa, Turkey
| | - Lütfü Bekar
- Department of Cardiology (Drs Bekar, Kalçık), Hitit University Faculty of Medicine, Çorum, Turkey
| | - Müjdat Aktaş
- Department of Cardiology (Dr Aktaş), Arnavutköy State Hospital, Istanbul, Turkey
| | | | - Macit Kalçık
- Department of Cardiology (Drs Bekar, Kalçık), Hitit University Faculty of Medicine, Çorum, Turkey
| | - Gökhan Aksan
- Department of Cardiology (Dr Aksan), Samsun Education and Research Hospital, Samsun, Turkey
| | - Göksel Cinier
- Department of Cardiology (Dr Cinier), Siyami Ersek Education and Research Hsopital, Istanbul, Turkey
| | - Kadriye Halli Akay
- Department of Cardiology (Dr Akay), Kocaeli State Hospital, Kocaeli, Turkey
| | - Nihat Pekel
- Department of Cardiology (Dr Pekel), Tekden Private Hospital Denizli, Turkey
| | - Utku Şenol
- Department of Cardiology (Dr Utku Şenol), Eskişehir Acıbadem Hospital, Eskişehir, Turkey
| | - Vahit Demir
- Department of Cardiology (Dr Demir), Yozgat City Hospital, Yozgat, Turkey
| | - Sinan İnci
- Department of Cardiology (Dr İnci), Aksaray University Faculty of Medicine, Aksaray
| | - Emir Derviş
- Department of Cardiology (Dr Derviş), Medipol University Faculty of Medicine, Istanbul, Turkey
| | - Bülent Özlek
- Department of Cardiology (Drs Başaran, Doğan, Özlek, Özlek, Çelik), Muğla Sıtkı Koçman University Faculty of Medicine, Muğla, Turkey
| | - Eda Özlek
- Department of Cardiology (Drs Başaran, Doğan, Özlek, Özlek, Çelik), Muğla Sıtkı Koçman University Faculty of Medicine, Muğla, Turkey
| | - Oğuzhan Çelik
- Department of Cardiology (Drs Başaran, Doğan, Özlek, Özlek, Çelik), Muğla Sıtkı Koçman University Faculty of Medicine, Muğla, Turkey
| | - Cem Çil
- Department of Cardiology (Dr Çil), Medlife Medical Center, Muğla, Turkey
| | - Murat Biteker
- Department of Cardiology (Dr Biteker), Private Fethiye Lokman Hekim Hospital, Mugla, Turkey
| |
Collapse
|